The "Monoclonal Antibody Therapeutics: From Analytics to Formulation Excellence" virtual masterclass offers a comprehensive exploration of this critical field in biopharmaceuticals. Over three intensive half-day sessions, participants will delve into cutting-edge advancements shaping the future of antibody-based therapies. This course covers innovative analytical methods, state-of-the-art formulation strategies, and crucial regulatory considerations, providing a holistic view of the complex challenges and opportunities in monoclonal antibody development and characterization.
Led by the distinguished Prof. Dr. Tudor Arvinte, a pioneer in protein formulation with over three decades of industry experience, this course bridges the gap between academic research and practical application. Participants will gain invaluable insights into innovative techniques developed by Therapeomic, examine historical trends in antibody formulations, and explore real-world case studies of both marketed antibodies and those in development.
From cutting-edge spectroscopy methods to high-throughput analysis platforms, this masterclass covers a wide spectrum of topics crucial for anyone working in the rapidly evolving field of antibody therapeutics. Whether you're involved in research and development, quality control, or regulatory affairs, this course offers a unique opportunity to enhance your expertise and stay at the forefront of this dynamic industry.
By combining theoretical knowledge with practical examples and interactive Q&A sessions, this masterclass provides a holistic view of the challenges and opportunities in monoclonal antibody formulation and characterization. Join us to gain the insights and skills needed to drive innovation in this critical area of modern medicine.
This introduction provides a broader overview of the course, highlighting its comprehensive nature, the expertise of the instructor, and the relevance of the content to various professionals in the field. It also emphasizes the balance between theoretical knowledge and practical application, which should appeal to a wide range of potential participants.
.webp)
Understand and apply novel analytical methods for characterizing antibody therapeutics.
Evaluate different types of aggregates and particulates in antibody formulations.
Implement high-throughput analysis and formulation strategies in antibody development.
Analyze historical trends and current practices in antibody formulation (1955-2023).
Develop strategies for antibody formulation based on case studies and regulatory considerations.
Apply knowledge to the development of biosimilar antibody products.
Understand methods for characterizing antibody interactions with human plasma and blood.
Interpret complex analytical data using advanced presentation techniques like the Therapeomic data wheel.
.png)
Tudor Arvinte, Ph.D., received his academic training in physics at the University of Jassy, Romania, and his Ph.D. in biophysics from the University of Düsseldorf, Germany. He performed his doctoral work and postdoctoral stage at the Max-Planck-Institute West Germany and held numerous research positions in Europe and the USA: at C.N.R.S., Orléans, France, at Cornell University, New York, at Texas A&M University, and at the Biophor Corporation, College Station, Texas, USA. In 1989 he joined Ciba-Geigy Pharmaceuticals in Horsham, England, and in 1994 he moved to Ciba-Geigy in Basel, Switzerland (Novartis since 1997). Until 2002 he worked as Head of Exploratory Formulation, Novartis Biotechnology Development & Production, Basel. T. Arvinte worked on the characterization and formulation of more than 200 protein and peptide drugs. Four of his protein formulations reached the market: the formulations were developed using High Throughput Analytic (HTA) and High Throughput Formulation (HTF) methods developed by T Arvinte. T. Arvinte has 90 publications, 12 book chapters, holds 15 patents on formulations of proteins, and gave more than 490 invited lectures at scientific meetings, regulatory bodies, and pharmaceutical companies. T. Arvinte was Titular Professor at the School of Pharmacy, University of Geneva, Switzerland where he is teaching a post-graduate course on “Formulation and delivery of protein biopharmaceuticals” until 2023. He co-founded Therapeomic, Inc., a biotech company focused on developing formulations for biopharmaceuticals in collaborations with pharmaceutical companies.
